TY - JOUR
TI - Sertraline for the treatment of depression in coronary artery disease and heart failure
AU - Parissis, J.
AU - Fountoulaki, K.
AU - Paraskevaidis, I.
AU - Kremastinos, D.T.
JO - Expert Opinion on Pharmacotherapy
PY - 2007
VL - 8
TODO - 10
SP - 1529-1537
PB - 
SN - 1465-6566, 1744-7666
TODO - 10.1517/14656566.8.10.1529
TODO - acetylsalicylic acid;  carbamazepine;  citalopram;  clomipramine;  clopidogrel;  clozapine;  cytochrome P450 1A2;  cytochrome P450 2C19;  cytochrome P450 2C9;  cytochrome P450 3A4;  desipramine;  escitalopram;  fluoxetine;  fluvoxamine;  imipramine;  interleukin 1;  lamotrigine;  midazolam;  norclozapine;  nortriptyline;  paroxetine;  placebo;  serotonin 2 receptor;  serotonin uptake inhibitor;  sertraline;  trazodone;  tricyclic antidepressant agent;  tumor necrosis factor alpha;  unindexed drug;  warfarin, cardiomyopathy;  cardiotoxicity;  clinical trial;  cognitive therapy;  comorbidity;  concentration response;  coronary artery disease;  depression;  diarrhea;  dose response;  drug absorption;  drug blood level;  drug competition;  drug dose comparison;  drug efficacy;  drug elimination;  drug induced headache;  drug mechanism;  drug megadose;  drug metabolism;  drug safety;  drug structure;  drug tolerability;  drug withdrawal;  ejaculation disorder;  fatigue;  heart arrhythmia;  heart failure;  heart infarction;  heart muscle conduction disturbance;  heart protection;  human;  insomnia;  libido disorder;  loose feces;  morbidity;  mortality;  nausea;  nonhuman;  orthostatic hypotension;  quality of life;  review;  risk factor;  side effect;  single drug dose;  somnolence;  sudden death;  tachycardia;  unspecified side effect;  xerostomia, Animals;  Antidepressive Agents;  Comorbidity;  Coronary Arteriosclerosis;  Depression;  Heart Failure, Congestive;  Humans;  Serotonin Uptake Inhibitors;  Sertraline;  Treatment Outcome
TODO - Depression is a common co-morbid condition in patients with cardiac disease and has been identified as an independent risk factor for increased morbidity and mortality. SSRIs are established agents for the treatment of depression and are well tolerated in patients with cardiac disease. SSRIs are a heterogeneous group of antidepressants, which apart from their common mechanism of action, differ substantially in their chemical structure, metabolism and pharmacokinetics. This article reviews experimental and clinical evidence on the safety and efficacy of the most extensively studied SSRI, sertraline, in depressed patients with coronary artery disease and heart failure. Intervention with sertraline has the potential to provide depressed patients with cardiac disease relief from their depressive symptoms, improvement in quality of life and a potential benefit in their cardiovascular risk profile. © 2007 Informa UK Ltd.
ER -